Phibro Animal Health Corp has a consensus price target of $17 based on the ratings of 4 analysts. The high is $21 issued by Roth MKM on September 1, 2023. The low is $13 issued by Barclays on May 10, 2024. The 3 most-recent analyst ratings were released by Barclays, Morgan Stanley, and Roth MKM on May 10, 2024, November 9, 2023, and September 1, 2023, respectively. With an average price target of $16.67 between Barclays, Morgan Stanley, and Roth MKM, there's an implied -12.05% downside for Phibro Animal Health Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/10/2024 | Buy Now | -31.4% | Barclays | Balaji Prasad | $10 → $13 | Maintains | Underweight | Get Alert |
11/09/2023 | Buy Now | -15.57% | Morgan Stanley | Erin Wright | $17 → $16 | Maintains | Equal-Weight | Get Alert |
09/01/2023 | Buy Now | 10.82% | Roth MKM | Brian Wright | → $21 | Reiterates | Buy → Buy | Get Alert |
08/31/2023 | Buy Now | -10.29% | Morgan Stanley | Erin Wright | $18 → $17 | Maintains | Equal-Weight | Get Alert |
08/29/2023 | Buy Now | 10.82% | Roth MKM | Brian Wright | → $21 | Reiterates | Buy → Buy | Get Alert |
07/27/2023 | Buy Now | -5.01% | Morgan Stanley | Erin Wright | $18 → $18 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
05/04/2023 | Buy Now | -5.01% | Morgan Stanley | Erin Wright | $19 → $18 | Maintains | Equal-Weight | Get Alert |
02/09/2023 | Buy Now | 0.26% | Morgan Stanley | Erin Wright | $20 → $19 | Maintains | Equal-Weight | Get Alert |
12/21/2022 | Buy Now | -5.01% | Roth Capital | Brian Wright | → $18 | Initiates | → Buy | Get Alert |
11/10/2022 | Buy Now | 5.54% | Morgan Stanley | Erin Wright | $21 → $20 | Maintains | Equal-Weight | Get Alert |
09/16/2022 | Buy Now | -10.29% | Barclays | Balaji Prasad | $22 → $17 | Maintains | Underweight | Get Alert |
08/26/2022 | Buy Now | 10.82% | Morgan Stanley | Erin Wright | $23 → $21 | Maintains | Equal-Weight | Get Alert |
07/25/2022 | Buy Now | 16.09% | Barclays | Balaji Prasad | → $22 | Downgrade | Equal-Weight → Underweight | Get Alert |
01/10/2022 | Buy Now | 21.37% | Barclays | Balaji Prasad | → $23 | Upgrade | Underweight → Equal-Weight | Get Alert |
11/18/2021 | Buy Now | 21.37% | Morgan Stanley | Erin Wright | — | Initiates | → Equal-Weight | Get Alert |
The latest price target for Phibro Animal Health (NASDAQ:PAHC) was reported by Barclays on May 10, 2024. The analyst firm set a price target for $13.00 expecting PAHC to fall to within 12 months (a possible -31.40% downside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Phibro Animal Health (NASDAQ:PAHC) was provided by Barclays, and Phibro Animal Health maintained their underweight rating.
The last upgrade for Phibro Animal Health Corp happened on January 10, 2022 when Barclays raised their price target to $23. Barclays previously had an underweight for Phibro Animal Health Corp.
The last downgrade for Phibro Animal Health Corp happened on July 25, 2022 when Barclays changed their price target from N/A to $22 for Phibro Animal Health Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Phibro Animal Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Phibro Animal Health was filed on May 10, 2024 so you should expect the next rating to be made available sometime around May 10, 2025.
While ratings are subjective and will change, the latest Phibro Animal Health (PAHC) rating was a maintained with a price target of $10.00 to $13.00. The current price Phibro Animal Health (PAHC) is trading at is $18.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.